Crisaborole
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 272 publications
Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).
Journal: JAAD international
Published: April 13, 2026
Crisaborole Reduced the Staphylococci but Increased Cutibacterium on the Skin Microbiome of Children with Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: March 23, 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.
Journal: Journal of drugs in dermatology : JDD
Published: March 11, 2026
Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options.
Journal: Expert review of clinical pharmacology
Published: March 11, 2026
Treatment of discoid lupus erythematosus with crisaborole.
Journal: The Journal of dermatological treatment
Published: March 11, 2026
Drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Comparison chart: Topical nonsteroidal drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.
Journal: The Journal of clinical and aesthetic dermatology
Published: February 06, 2026
Guidelines of care for the management of atopic dermatitis in pediatric patients.
Journal: Journal of the American Academy of Dermatology
Published: January 15, 2026
Benzoxaborole and Beyond: The Emergence of Cyclic Hemiboronic Acids as a Versatile Chemotype in Medicine, Catalysis, and Materials.
Journal: Chemical reviews
Published: January 13, 2026
Recent advances in the synthesis and applications of oxaborole derivatives.
Journal: Organic & biomolecular chemistry
Published: January 13, 2026
Last Updated: 04/28/2026